14
Participants
Start Date
February 24, 2020
Primary Completion Date
June 28, 2024
Study Completion Date
June 28, 2024
Benralizumab
Benralizumab 30 mg administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period
Placebo
Placebo administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period
Humanitas Clinical and Research Hospital, Rozzano
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
Humanitas Clinical and Research Center
OTHER